title: Kinin B1 receptor expression on multiple sclerosis mononuclear cells: correlation with magnetic resonance imaging T2-weighted lesion volume and clinical disability.
abstract: BACKGROUND
  We have previously shown that the inducible kinin B(1) receptor is expressed on T lymphocytes during relapses and progression in multiple sclerosis.
  
  
  OBJECTIVE
  To evaluate the correlation between the expression of B1 receptor on peripheral blood mononuclear cells derived from patients who have multiple sclerosis with serial, clinical magnetic resonance imaging and immunological study-derived measures.
  
  
  METHODS
  Using frozen samples obtained from a high-frequency magnetic resonance imaging-immunological study, we analyzed B1 receptor messenger RNA (mRNA) expression in peripheral blood-derived mononuclear cells serially collected from 6 patients with multiple sclerosis and 8 healthy control subjects by semiquantitative radioactive duplex reverse transcriptase-polymerase chain reaction amplification. Time-course kinin B1-actin mRNA ratios were subsequently compared with corresponding clinical magnetic resonance imaging and immune parameters.
  
  
  RESULTS
  The time-course kinin B1-actin mRNA ratio correlated positively with the Expanded Disability Status Scale index (P<.001), occurrence of clinical relapse (P = .02), volume of lesion on T2-weighted images (P<.003) and interleukin 2 receptor and major histocompatibility complex class II expression on CD4+ lymphocytes, but not with gadolinium-enhancing lesions. The time-course kinin B1-actin mRNA ratios were 5 to 25 times lower in samples derived from healthy controls.
  
  
  CONCLUSIONS
  The correlation of kinin B1 receptor mRNA levels with dynamic clinical and magnetic resonance imaging measures suggests that expression of this receptor can serve as an index of disease activity in multiple sclerosis.
authors.affiliation: Neuroimmunology Unit, Montréal Neurological Institute, McGill University, Montréal, Québec, Canada. a.prat@umontreal.ca
authors.forename: Alexandre
authors.initials: A
authors.lastname: Prat
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Biernacki
authors.forename: Tanya
authors.initials: T
authors.lastname: Saroli
authors.forename: John E
authors.initials: JE
authors.lastname: Orav
authors.forename: Charles R G
authors.initials: CR
authors.lastname: Guttmann
authors.forename: Howard L
authors.initials: HL
authors.lastname: Weiner
authors.forename: Samia J
authors.initials: SJ
authors.lastname: Khoury
authors.forename: Jack P
authors.initials: JP
authors.lastname: Antel
mesh_terms: D000328:Adult; D015496:CD4-Positive T-Lymphocytes / Q000378:metabolism; D004185:Disability Evaluation; D005260:Female; D015870:Gene Expression / Q000502:physiology*; D005802:Genes, MHC Class II / Q000502:physiology; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000378:metabolism*; D009103:Multiple Sclerosis / Q000235:genetics / Q000378:metabolism*; D012333:RNA, Messenger / Q000096:biosynthesis; D043783:Receptor, Bradykinin B1 / Q000235:genetics / Q000378:metabolism*; D015375:Receptors, Interleukin-2 / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods; D013223:Statistics as Topic; D013997:Time Factors
chemical_list: D012333:RNA, Messenger; D043783:Receptor, Bradykinin B1; D015375:Receptors, Interleukin-2